甲状腺弥漫性大B细胞淋巴瘤临床病理特征、基因突变谱及预后分析
|
|
杜沚珊, 王玥, 石子旸, 施晴, 易红梅, 董磊, 王黎, 程澍, 许彭鹏, 赵维莅
|
Clinicopathologic characteristics, gene mutation profile and prognostic analysis of thyroid diffuse large B-cell lymphoma
|
|
DU Zhishan, WANG Yue, SHI Ziyang, SHI Qing, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili
|
|
表1 原发和继发甲状腺DLBCL患者临床病理特征分析
|
Tab 1 Analysis of clinicopathologic characteristics in patients with primary and secondary thyroid DLBCL
|
|
| Characteristic | Primary thyroid DLBCL (n=23) | Secondary thyroid DLBCL (n=43) | χ2 | P value |
|---|
| Gender/n(%) | | | 0.303 | 0.582 | | Male | 7 (30.4) | 16 (37.2) | | | | Female | 16 (9.6) | 27 (62.8) | | | | Age/n(%) | | | 0.422 | 0.516 | | ≤60 years | 11 (47.8) | 17 (39.5) | | | | >60 years | 12 (52.2) | 26 (60.5) | | | | ECOG score/n(%) | | | 0.229 | 0.632 | | 0‒1 score | 21 (91.3) | 36 (83.7) | | | | ≥2 score | 2 (8.7) | 7 (16.3) | | | | Ann Arbor stage/n(%) | | | 33.226 | 0.000 | | Ⅰ‒Ⅱ | 23 (100) | 11 (25.6) | | | | Ⅲ‒Ⅳ | 0 (0) | 32 (74.4) | | | | LDH/n(%) | | | 4.108 | 0.043 | | Normal | 14 (60.9) | 15 (34.9) | | | | Elevated | 9 (39.1) | 28 (65.1) | | | | Extranodal involvement/n(%) | | | 26.012 | 0.000 | | 0‒1 | 23 (100) | 15 (34.9) | | | | ≥2 | 0 (0) | 28 (65.1) | | | | Hans/n(%) | | | 4.694 | 0.030 | | GCB | 18/21 (85.7) | 24/41 (58.5) | | | | non-GCB | 3/21 (14.3) | 17/41 (41.5) | | | | DE/n(%) | | | 4.933 | 0.026 | | Yes | 1/17 (5.9) | 14/35 (40.0) | | | | No | 16/17 (94.1) | 21/35 (60.0) | | | | IPI/n(%) | | | 12.476 | 0.000 | | 0‒2 score | 20 (87.0) | 18 (41.9) | | | | 3‒5 score | 3 (13.0) | 25 (58.1) | | | | Thyroidectomy/n(%) | | | 6.242 | 0.012 | | Yes | 11 (47.8) | 8 (18.6) | | | | No | 12 (52.2) | 35 (81.4) | | |
|
|
|